Developer docs
API playgroundTry for free, no card

Search company profiles

Manifold Bio

Full company profile

uuid0000cnx

Namestring
Manifold Bio
Legal namestring
Manifold Biotechnologies, Inc.
Websiteurl
manifold.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Manifold Bio is a Boston-based, venture-backed platform therapeutics company founded in 2020 out of George Church's Harvard lab. It builds an AI-guided direct-to-vivo drug discovery platform, the mDesign engine, that combines AI-powered protein design with massively multiplexed in vivo screening to engineer tissue-targeted biologics. The company's wetware layer is built around mCodes, inert peptide barcodes decoded via next-generation sequencing that allow quantification of hundreds to thousands of candidate molecules across tissues in a single animal, and an mShuttle Portfolio of tissue-targeting shuttle molecules, including blood-brain barrier shuttles for CNS delivery. Supporting AI assets include mBER, an open-source AlphaFold-Multimer-based framework for de novo antibody binder generation, and EpiTome, a proprietary epitope-to-biodistribution data resource that feeds into a longer-term "virtual organism" predictive model of in vivo biology.

The company's internal pipeline is anchored in CNS-targeted therapeutics for Alzheimer's and Parkinson's disease (antibodies and oligonucleotides against Abeta, tau, and alpha-synuclein) and is expanding into peripheral-targeted cardiometabolic indications. Manifold operates a partnership-driven business model, monetizing its platform through research collaboration and license agreements with pharmaceutical partners structured around upfront payments, research/preclinical/clinical/commercial milestones, and tiered royalties. Its flagship commercial relationship is a November 2025 collaboration with Roche for next-generation BBB shuttles, which delivered a $55 million upfront and over $2 billion in potential milestones plus royalties; Manifold leads discovery while Roche leads preclinical, clinical, and commercialization, and Manifold retains rights to co-fund one program for enhanced royalties and to apply shuttles to non-licensed targets. A March 2026 joint study with NVIDIA validated million-scale AI-driven binder design using the company's platform, and the open-sourcing of mBER on GitHub signals a strategy of building an external ecosystem around its core AI tools.

Short descriptiontext

Manifold Bio is a Boston-based platform therapeutics company that combines AI-guided protein design with massively multiplexed in vivo screening to discover tissue-targeted biologics, serving pharmaceutical partners through licensing deals anchored by a flagship Roche BBB-shuttle collaboration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI-guided drug discovery, in vivo screening, tissue-targeted biologics, protein engineering platform, multiplexed barcoding
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-Guided Biologics Drug Discovery Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnerships and License Agreements
TypeLicensing Royalties
Description

Manifold Bio generates revenue through research collaboration and license agreements with pharmaceutical partners. These deals include upfront payments, research and preclinical milestones, clinical milestones, and commercial milestones plus tiered royalties. The company also retains rights to co-fund development of product candidates for enhanced royalty participation.

manifold.bio
2Venture Funding
TypeSubscription Recurring
Description

Series A funding round of $40 million led by Triatomic Capital to support drug programs, expand protein engineering platform, and enable internal development in oncology.

vcaonline.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Manifold Bio operates a direct-to-vivo drug discovery platform that combines massively multiplexed in vivo screening with AI-guided protein design to engineer tissue-targeted biologics including antibodies and oligonucleotides. The platform is built around the proprietary mDesign Engine and supporting technologies such as mCodes molecular barcoding, the mBER AI antibody design framework, and the mShuttle Portfolio for tissue-specific delivery including BBB shuttles. Revenue is generated primarily by licensing the platform and shuttle technology to global pharmaceutical partners through research collaborations with upfront payments, milestones, and tiered royalties, while the company retains an internal pipeline of CNS and cardiometabolic therapeutic candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 68% of targets achieved specific binder identification in NVIDIA validation study
+3 more records
Product overview1 text field

Manifold Bio is a platform therapeutics company offering a unified direct-to-vivo drug discovery platform consisting of multiple integrated products. The core mDesign Engine combines AI-guided protein design with massively multiplexed in vivo screening. Supporting technologies include mCodes (molecular barcoding), mBER (open-source AI antibody design framework), and the mShuttle Portfolio for tissue-targeted delivery. The company is building EpiTome, a proprietary epitope-to-biodistribution data resource, toward a virtual organism model. The platform enables testing thousands to millions of biologic variants directly in living systems for tissue-targeted biologics development.

Product and service2 records
1Direct-to-Vivo Discovery Platform (mDesign Engine)
CategoryAI drug discovery platform
Description

AI-guided direct-to-vivo drug discovery platform that combines massively multiplexed in vivo screening with AI-powered protein design to engineer tissue-targeted biologics including antibodies and oligonucleotides, with the long-term goal of building a virtual organism model.

2mShuttle Portfolio (BBB Shuttles and Tissue-Targeting Shuttles)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-16
Description

Joint study to validate NVIDIA's generative model Proteina-Complexa for protein binder design. Manifold used its proprietary platform to test 1 million binder designs against 127 targets in a single multiplexed experiment, measuring over 100 million protein-protein interactions. Study established Proteina-Complexa as competitive with state-of-the-art methods, validating the approach of matching generative AI throughput with experimental validation at equivalent scale.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Strategic research collaboration and license agreement to develop multiple next-generation blood-brain barrier (BBB) shuttles for neurological and neurodegenerative diseases. Manifold receives $55 million upfront and potential for over $2 billion in research, preclinical, clinical, and commercial milestones, plus tiered royalties. Manifold leads discovery while Roche leads preclinical, clinical, and commercialization. Manifold retains right to co-fund development of one program for enhanced royalties and rights to apply BBB shuttles to non-licensed targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Generate Biomedicines is a generative biology platform using AI to design novel protein therapeutics across modalities. Directly comparable to Manifold's mDesign engine and AI-guided protein design approach, both targeting de novo biologics creation rather than screening natural repertoires.

TypeDirect peer
Description

Absci combines generative AI with a wet-lab platform for de novo antibody design and synthesis. Overlaps with Manifold's mBER framework and EpiTome data resource, both focused on AI-driven antibody binder generation at scale.

TypeDirect peer
Description

BigHat Biosciences uses ML-guided antibody design integrated with high-throughput wet-lab validation, similar to Manifold's ML2 (Machine Learning + Multiplexed Libraries) approach combining AI design with in vivo/in vitro measurement.

TypeDirect peer
Description

Cradle applies generative AI and protein language models to engineer improved biologics. Shares Manifold's emphasis on AI-guided protein engineering for therapeutic applications and serves pharma partners with platform licensing.

TypeBroad incumbent
Description

Insitro is a larger, well-funded AI-driven drug discovery company combining ML with high-throughput biology. While broader in scope (small molecules, cell biology, multiple therapeutic areas) than Manifold, it shares the ML × wet-lab integration thesis and pharma partnership model.

TypeDirect peer
Description

Genesis Therapeutics develops AI models for protein structure and molecular design to discover novel therapeutics. Comparable to Manifold in combining generative protein modeling with pharma partnerships and target-based drug discovery.

7Isomorphic Labs
TypeBroad incumbent
Description

Isomorphic Labs (Alphabet/DeepMind spinoff) applies AlphaFold-derived AI to drug discovery. Significantly larger and broader in scope than Manifold, but competes for similar pharma partnerships and AI-bio talent targeting novel protein therapeutics.

TypeEmerging player
Description

EvolutionaryScale is building frontier AI models for biology (ESM family) including protein design. Adjacent to Manifold's mBER/mDesign work; provides complementary foundational AI tools rather than a direct competing drug discovery platform.

TypeEmerging player
Description

Adaptyv Bio operates a high-throughput protein engineering platform combining automated wet-lab experimentation with ML-driven protein design. Overlaps with Manifold's ML2 approach at smaller scale and narrower therapeutic scope.

TypeBroad incumbent
Description

Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with ML at industrial scale. Broad incumbent in the AI-bio space, more focused on small molecules and target ID but addresses similar pharma partnership customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Manifold Bio

AI-Guided Biologics Drug Discovery Platformmanifold.bio

Manifold Bio is a Boston-based platform therapeutics company that combines AI-guided protein design with massively multiplexed in vivo screening to discover tissue-targeted biologics, serving pharmaceutical partners through licensing deals anchored by a flagship Roche BBB-shuttle collaboration.

What Manifold Bio does

Manifold Bio is a Boston-based, venture-backed platform therapeutics company founded in 2020 out of George Church's Harvard lab. It builds an AI-guided direct-to-vivo drug discovery platform, the mDesign engine, that combines AI-powered protein design with massively multiplexed in vivo screening to engineer tissue-targeted biologics. The company's wetware layer is built around mCodes, inert peptide barcodes decoded via next-generation sequencing that allow quantification of hundreds to thousands of candidate molecules across tissues in a single animal, and an mShuttle Portfolio of tissue-targeting shuttle molecules, including blood-brain barrier shuttles for CNS delivery. Supporting AI assets include mBER, an open-source AlphaFold-Multimer-based framework for de novo antibody binder generation, and EpiTome, a proprietary epitope-to-biodistribution data resource that feeds into a longer-term "virtual organism" predictive model of in vivo biology.

The company's internal pipeline is anchored in CNS-targeted therapeutics for Alzheimer's and Parkinson's disease (antibodies and oligonucleotides against Abeta, tau, and alpha-synuclein) and is expanding into peripheral-targeted cardiometabolic indications. Manifold operates a partnership-driven business model, monetizing its platform through research collaboration and license agreements with pharmaceutical partners structured around upfront payments, research/preclinical/clinical/commercial milestones, and tiered royalties. Its flagship commercial relationship is a November 2025 collaboration with Roche for next-generation BBB shuttles, which delivered a $55 million upfront and over $2 billion in potential milestones plus royalties; Manifold leads discovery while Roche leads preclinical, clinical, and commercialization, and Manifold retains rights to co-fund one program for enhanced royalties and to apply shuttles to non-licensed targets. A March 2026 joint study with NVIDIA validated million-scale AI-driven binder design using the company's platform, and the open-sourcing of mBER on GitHub signals a strategy of building an external ecosystem around its core AI tools.

Manifold Bio firmographics

Firmographics
Name
Manifold Bio
Legal name
Manifold Biotechnologies, Inc.
Website
https://manifold.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Manifold Bio is a Boston-based platform therapeutics company that combines AI-guided protein design with massively multiplexed in vivo screening to discover tissue-targeted biologics, serving pharmaceutical partners through licensing deals anchored by a flagship Roche BBB-shuttle collaboration.
Ownership category
akta.pro rank

Manifold Bio industry classification

Industry
Product category
AI-Guided Biologics Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI-guided drug discovery
  • In vivo screening
  • Tissue-targeted biologics
  • Protein engineering platform
  • Multiplexed barcoding

Where Manifold Bio is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Manifold Bio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. Strategic Partnerships and License Agreements: Manifold Bio generates revenue through research collaboration and license agreements with pharmaceutical partners. These deals include upfront payments, research and preclinical milestones, clinical milestones, and commercial milestones plus tiered royalties. The company also retains rights to co-fund development of product candidates for enhanced royalty participation.
  2. Venture Funding: Series A funding round of $40 million led by Triatomic Capital to support drug programs, expand protein engineering platform, and enable internal development in oncology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Manifold Bio product offering

Product offering

Core offering

Manifold Bio operates a direct-to-vivo drug discovery platform that combines massively multiplexed in vivo screening with AI-guided protein design to engineer tissue-targeted biologics including antibodies and oligonucleotides. The platform is built around the proprietary mDesign Engine and supporting technologies such as mCodes molecular barcoding, the mBER AI antibody design framework, and the mShuttle Portfolio for tissue-specific delivery including BBB shuttles. Revenue is generated primarily by licensing the platform and shuttle technology to global pharmaceutical partners through research collaborations with upfront payments, milestones, and tiered royalties, while the company retains an internal pipeline of CNS and cardiometabolic therapeutic candidates.

Product overview

Manifold Bio is a platform therapeutics company offering a unified direct-to-vivo drug discovery platform consisting of multiple integrated products. The core mDesign Engine combines AI-guided protein design with massively multiplexed in vivo screening. Supporting technologies include mCodes (molecular barcoding), mBER (open-source AI antibody design framework), and the mShuttle Portfolio for tissue-targeted delivery. The company is building EpiTome, a proprietary epitope-to-biodistribution data resource, toward a virtual organism model. The platform enables testing thousands to millions of biologic variants directly in living systems for tissue-targeted biologics development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Direct-to-Vivo Discovery Platform (mDesign Engine) AI-guided direct-to-vivo drug discovery platform that combines massively multiplexed in vivo screening with AI-powered protein design to engineer tissue-targeted biologics including antibodies and oligonucleotides, with the long-term goal of building a virtual organism model.
  • mShuttle Portfolio (BBB Shuttles and Tissue-Targeting Shuttles)

Quantifiable outcome

  • 68% of targets achieved specific binder identification in NVIDIA validation study
  • +3 more outcomes

Companies that use Manifold Bio

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Manifold Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Manifold Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • NVIDIAcoreTechnology or Integration · 16 March 2026Joint study to validate NVIDIA's generative model Proteina-Complexa for protein binder design. Manifold used its proprietary platform to test 1 million binder designs against 127 targets in a single multiplexed experiment, measuring over 100 million protein-protein interactions. Study established Proteina-Complexa as competitive with state-of-the-art methods, validating the approach of matching generative AI throughput with experimental validation at equivalent scale.
  • RocheflagshipStrategic or Co-development Partner · 3 November 2025Strategic research collaboration and license agreement to develop multiple next-generation blood-brain barrier (BBB) shuttles for neurological and neurodegenerative diseases. Manifold receives $55 million upfront and potential for over $2 billion in research, preclinical, clinical, and commercial milestones, plus tiered royalties. Manifold leads discovery while Roche leads preclinical, clinical, and commercialization. Manifold retains right to co-fund development of one program for enhanced royalties and rights to apply BBB shuttles to non-licensed targets.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Manifold Bio competitors and assessment

Company assessment

Direct peers

  • Generate Biomedicines: Generate Biomedicines is a generative biology platform using AI to design novel protein therapeutics across modalities. Directly comparable to Manifold's mDesign engine and AI-guided protein design approach, both targeting de novo biologics creation rather than screening natural repertoires.
  • Absci: Absci combines generative AI with a wet-lab platform for de novo antibody design and synthesis. Overlaps with Manifold's mBER framework and EpiTome data resource, both focused on AI-driven antibody binder generation at scale.
  • BigHat Biosciences: BigHat Biosciences uses ML-guided antibody design integrated with high-throughput wet-lab validation, similar to Manifold's ML2 (Machine Learning + Multiplexed Libraries) approach combining AI design with in vivo/in vitro measurement.
  • Cradle Bio: Cradle applies generative AI and protein language models to engineer improved biologics. Shares Manifold's emphasis on AI-guided protein engineering for therapeutic applications and serves pharma partners with platform licensing.
  • Genesis Therapeutics: Genesis Therapeutics develops AI models for protein structure and molecular design to discover novel therapeutics. Comparable to Manifold in combining generative protein modeling with pharma partnerships and target-based drug discovery.

Broad incumbents

  • Insitro: Insitro is a larger, well-funded AI-driven drug discovery company combining ML with high-throughput biology. While broader in scope (small molecules, cell biology, multiple therapeutic areas) than Manifold, it shares the ML × wet-lab integration thesis and pharma partnership model.
  • Isomorphic Labs: Isomorphic Labs (Alphabet/DeepMind spinoff) applies AlphaFold-derived AI to drug discovery. Significantly larger and broader in scope than Manifold, but competes for similar pharma partnerships and AI-bio talent targeting novel protein therapeutics.
  • Recursion Pharmaceuticals: Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with ML at industrial scale. Broad incumbent in the AI-bio space, more focused on small molecules and target ID but addresses similar pharma partnership customers.

Emerging players

  • EvolutionaryScale: EvolutionaryScale is building frontier AI models for biology (ESM family) including protein design. Adjacent to Manifold's mBER/mDesign work; provides complementary foundational AI tools rather than a direct competing drug discovery platform.
  • Adaptyv Bio: Adaptyv Bio operates a high-throughput protein engineering platform combining automated wet-lab experimentation with ML-driven protein design. Overlaps with Manifold's ML2 approach at smaller scale and narrower therapeutic scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Manifold Bio social profiles

Digital presence

Manifold Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Manifold Bio leadership team

Management profile

Number of profiles

Profiles11 records

Manifold Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Manifold Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Manifold Bio

What does Manifold Bio do?

Manifold Bio operates a direct-to-vivo drug discovery platform that combines massively multiplexed in vivo screening with AI-guided protein design to engineer tissue-targeted biologics including antibodies and oligonucleotides. The platform is built around the proprietary mDesign Engine and supporting technologies such as mCodes molecular barcoding, the mBER AI antibody design framework, and the mShuttle Portfolio for tissue-specific delivery including BBB shuttles. Revenue is generated primarily by licensing the platform and shuttle technology to global pharmaceutical partners through research collaborations with upfront payments, milestones, and tiered royalties, while the company retains an internal pipeline of CNS and cardiometabolic therapeutic candidates.

Is Manifold Bio a public or private company?

Manifold Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Manifold Bio founded?

Manifold Bio was founded in 2020. It employs 51 to 100 people.

Where is Manifold Bio based?

Manifold Bio is headquartered in Boston, United States, in the North America region.

How does Manifold Bio make money?

Two revenue lines are on record. Strategic Partnerships and License Agreements are the primary driver. The others are venture Funding.

Who are Manifold Bio's main competitors?

Direct peers on record are Generate Biomedicines, Absci, BigHat Biosciences, Cradle Bio and Genesis Therapeutics. Broad incumbents are Insitro, Isomorphic Labs and Recursion Pharmaceuticals. Emerging players are EvolutionaryScale and Adaptyv Bio.

Does Manifold Bio have an API?

No public API is recorded for Manifold Bio.

What industry is Manifold Bio in?

Manifold Bio's product category is AI-Guided Biologics Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NVIDIA BlogDesigning Protein Binders Using the Generative Model Proteina-ComplexaNVIDIA released Proteina-Complexa, a generative AI model for the de novo design of protein binders and enzymes, using a partially latent flow-matching framework that simultaneously co-designs fully atomistic backbone structures, side-chains, and amino acid sequences. The model was trained on over one million curated experimental and predicted protein structures and integrates inference-time compute scaling with search algorithms such as Beam Search and Best-of-N to optimize candidate generation and binder quality. Extensive experimental validation across tens of millions of in silico candidates tested against 133 distinct protein and small-molecule targets, conducted with collaborators including Manifold Bio, Novo Nordisk, Viva Biotech, Duke University, and the University of Cambridge, demonstrated the generation of high-affinity binders with nano- and picomolar affinities, including for previously intractable polar targets such as carbohydrate molecules on red blood cells.MorningstarManifold Bio Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design with NVIDIAManifold Bio announced a joint study with NVIDIA to validate Proteina-Complexa, NVIDIA's generative model for protein binder design, using Manifold's proprietary platform to test 1 million binder designs against 127 targets in a single multiplexed experiment measuring over 100 million protein-protein interactions.BioSpaceManifold Bio Demonstrates Million-Scale Experimental Validation of AI-Driven Protein Binder Design with NVIDIAManifold Bio, a Boston-based platform therapeutics company, announced a joint study with NVIDIA to validate NVIDIA's generative model Proteina-Complexa for protein binder design. The company tested 1 million binder designs against 127 targets in a single multiplexed experiment, measuring over 100 million protein-protein interactions and identifying specific binders to 68% of targets tested. This study establishes Proteina-Complexa as competitive with state-of-the-art methods and validates the approach of matching generative AI throughput with experimental validation at equivalent scale.BioSpaceThe New Gold Rush in Brain ScienceVenture capitalists interviewed at the J.P. Morgan Healthcare Conference reported sustained investment interest in neuroscience and CNS drug development for 2026, driven by advances in biomarkers, brain mapping, and AI enabling better patient segmentation and disease understanding. Major pharma deals in 2025 included Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies, Sanofi's $470 million purchase of Vigil Neuroscience, and Roche's $55 million collaboration with Manifold Bio, though investors acknowledged significant risks following notable 2025 failures including Novo Nordisk's semaglutide and Bristol Myers Squibb's Cobenfy. The neurotech sector is also experiencing rapid growth, with the global neurotechnology market projected to reach $52.86 billion by 2034, spurred by developments in neuromodulation devices, FDA approvals like Flow Neuroscience's home-use depression treatment, and Neuralink's announced plans for high-volume brain-computer interface production in 2026.AionlabsSummarizing Pharma-Biotech Deals 2025The article analyzes four major trends driving biopharma deals in 2025: AI integration in drug discovery (with deals like Takeda-Nabla Bio worth up to $1B, Merck KGaA-Valo Health up to $3B, and Roche-Manifold Bio up to $2B), mega-acquisitions in metabolic and obesity treatments (including Pfizer-Metsera at $7B and Novo Nordisk-Akero at $5.2B), strategic platform acquisitions (Novartis-Avidity Biosciences at $12B and BMS-Orbital at $1.5B), and the emergence of Chinese biotech as a key innovation hub (with Western companies investing approximately $66B in Chinese-developed assets). The analysis of 260 deals totaling nearly $280B in disclosed value identifies oncology, immunology, and metabolic disorders as the leading therapeutic areas, while Eli Lilly led by deal count with 24 transactions, nearly double that of Sanofi and Novartis.SynBioBetaManifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics PlatformManifold Bio has appointed Paula Cobb as Chief Operating Officer to strengthen its executive leadership team as the company scales its AI-guided drug discovery platform that integrates in vivo data generation with protein design for tissue-targeted biologics. Cobb brings operational expertise from prior roles at Prothena, Affinia Therapeutics, Decibel Therapeutics, and Biogen, and will focus on scaling the company's platform, advancing internal programs, and building partnerships. The leadership expansion follows the company's prior appointment of Kimberly Scearce-Levie as CSO and positions Manifold Bio to capitalize on its existing deal with Roche.citybizManifold Bio Appoints Paula Cobb as Chief Operating OfficerManifold Bio has appointed Paula Cobb as Chief Operating Officer to lead operational scaling and business strategy as the company expands its executive leadership team. This move supports the growth of Manifold's AI-guided drug discovery platform, which recently secured a partnership deal with Roche.PharmiWeb.comManifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics PlatformManifold Bio, a platform therapeutics company based in Boston, announced the expansion of its leadership team with the appointment of Paula Cobb as COO. The company is scaling its AI-guided drug discovery platform, which combines high-throughput in vivo data with AI protein design, to develop tissue-targeted biologics and expand its partnerships, including a recent deal with Roche.Business Wire BlogManifold Bio Expands Leadership Team to Drive its AI + In Vivo Targeted Biologics PlatformManifold Bio, a Boston-based platform therapeutics company, announced the appointment of Paula Cobb as Chief Operating Officer as part of an expansion of its executive leadership team. Cobb joins from the Board of Directors at Prothena Corporation and brings senior strategy and operations experience from Affinia Therapeutics, Decibel Therapeutics, and Biogen. The company stated the appointment will support scaling its AI-guided drug discovery platform and advancing its internal pipeline alongside strategic partnerships.Pulse 2.0Manifold Bio And Roche Form Strategic Collaboration To Develop Next-Generation Brain Shuttles For Neurological DiseasesManifold Bio announced a major research collaboration and license agreement with Roche to develop next-generation blood-brain barrier (BBB) shuttles for neurological and neurodegenerative diseases, combining Manifold's AI-guided discovery platform with Roche's brain-targeted therapeutics expertise. Under the terms, Manifold will receive $55 million upfront and may earn over $2 billion in research, preclinical, clinical, and commercial milestone payments, plus tiered royalties. Manifold will lead discovery of novel BBB shuttles while Roche oversees preclinical, clinical, and commercialization efforts.